Active mutations of a certain signaling receptor protein called KIT tyrosine kinase are found in several cancers, such as acute myeloid leukemia (AML). However, the different locations in the AML cells where KIT induces cancer-specific signaling remain unclear. Now, a group of scientists has aimed to answer this question by using a newly synthesized compound (along with other existing ones) that targets intracellular transport, which may offer an attractive strategy to combat cancer.
